Addressing vaccine hesitancy in challenging times: ECDC workshop at European Health Forum Gastein 2017
ECDC is hosting a workshop at the European Health Forum Gastein (EHFG) 2017, highlighting the complex nature of vaccine hesitancy, as well as the necessity for an inter-sectorial approach and political leadership.
European Immunisation Week April, 2017
European Immunization Week (EIW) is celebrated across the European Region every April to raise awareness of the importance of immunization for people’s health and well-being. Under the slogan "Vaccines work" EIW 2017 focuses on the need for and benefits of immunization at every stage in life.
WHO statement: 12th meeting of the Emergency Committee under the International Health Regulations Emergency (IHR) regarding the international spread of poliovirus
The conclusions of the IHR Emergency Committee do not change the ECDC risk assessment for Europe.
Five infectious diseases accounted for 75% of reported cases in EU - summary report
Chlamydia infection, campylobacteriosis, salmonellosis, gonorrhoea and tuberculosis were the most commonly reported notifiable infectious diseases in the EU and EEA in 2014.
Workshop: Finding the balance in life-course vaccination
The main objectives of the session are to: Raise awareness about the value and opportunities of life-course vaccination, Build understanding of the challenges faced at decision-making level to assess such a shift, Discuss the evidence necessary to help prioritising vaccinations across age groups, Prompt reflection on relevant ways forward and action at EU and national level.
European Immunisation Week, 2012
ECDC is marking European Immunisation Week with a focus on assisting EU Member States eliminate measles in their population. The root cause of the continued measles transmission in the EU is the sub-optimal uptake of MMR vaccination over several years.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescents
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.
No association found between pandemic influenza vaccination and Guillain-Barre Syndrome in Europe
Due to an association that was observed in the United States between a swine-flu based human influenza vaccine developed in 1976 and the disease acute polyneuropathy Guillain-Barré syndrome (GBS) (1,2), GBS was one of the adverse events that was monitored in Europe and North America (3) following the 2009 influenza pandemic vaccination campaigns.